Non-exclusive discount agreement for Fampridine (Open-House model)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 29, 2028 · 550 days left·Open·Supplies·Framework

Inscrivez-vous pour sauvegarder Open documents

Structured notice only

Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fampridin (ATC-Code nach WHO: N07XX07)

50/100

Score d'opportunité

Needs reviewLow complexity

SuppliesFrameworkOpen

Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No minimum volumes; actual demand is unknown and depends on physician prescribing behavior and patient numbers.

The buyer may terminate the open house if exclusive agreements are concluded, typically 8-12 months after publication.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Aperçu

Moderate opportunity

Faits clés

Framework procurement
Supplies contract
1 lot
Duration until Feb 2028
Entering into non-exclusive discount agreements for Fampridine
No minimum purchase quantities

Afficher le résumé complet

This tender invites pharmaceutical companies to enter into non-exclusive discount agreements for the active ingredient Fampridine (ATC N07XX07) under §130a SGB V via an Open-House model. All eligible companies can participate without exclusivity. No minimum purchase quantities are guaranteed, and the agreement ends by 29 February 2028. The buyer is AOK PLUS for the regions of Saxony and Thuringia. No estimated value is provided.

Risques

No minimum volumes; actual demand is unknown and depends on physician prescribing behavior and patient numbers.

The buyer may terminate the open house if exclusive agreements are concluded, typically 8-12 months after publication.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

Must be a pharmaceutical entrepreneur per §4 Abs.18 AMG
No Russian sanctions ties per EU Regulation 833/2014

Eligibility

No exclusion grounds per §§123,124 GWB

Les exigences peuvent être incomplètes.

Acheteur

Nom

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen

Localisation

Erfurt, DEU

[email protected]

Site web

www.aok.de/pk/plus/

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive discount agreement for Fampridine (Open-House model)

Establishment of a non-exclusive framework agreement for Fampridine under §130a SGB V. No minimum volumes, no exclusivity.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Feb 2026 - Feb 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 29, 2028

Détails de la procédure

Date de publication: 18 Dec 2025
Langues: German

Métadonnées de référence

Base juridique: 32014L0024

Identifiants de référence

ID de l'appel d'offres: 848406-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3